November 11, 2010
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
Summary
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
Summary
Gilenya became available in the US on Oct 4. Reports indicate just 13 enrollment forms within the first week. Numerous challenges lie ahead for a very effective therapy with very high expectations.
Analysis
Novartis has their work cut-out for them. While Gilenya holds the spotlight, the therapy has limited time before additional oral MS medications crowd the market. Gilenya comes with a significant monitoring requirement, along with safety concerns shared by both physicians and patients. Insurance coverage is a potential problem due to the pricing. Additional factors, along with market dynamics, make this launch and the ensuing year a challenge. Upcoming therapeutic agents in 2011 through 2013 are diverse, and may fill specific niches.
***********************************************************
“Providing You with ‘MS Views and News’, is what we do“
Keep Informed and up–to–date with information concerning
Multiple Sclerosis when registered at
the MS Views and News website.
****************************************************************
Disclaimer: ‘MS Views and News’ (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
. ****************************************************************
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews